Genetic factors make a substantial contribution to inter-individual variability in cognitive function. A recent meta-analysis of genome-wide association studies identified two loci, AKAP6 and MIR2113, that are associated with general cognitive function. Here, we extend this previous research by investigating the association of MIR2113 and AKAP6 with baseline and longitudinal non-linear change across a broad spectrum of cognitive domains in a community-based cohort of older adults without dementia. Two single nucleotide polymorphisms (SNPs), MIR211-rs10457441 and AKAP6-rs17522122 were genotyped in 1570 non-demented older Australians of European ancestry, who were examined up to 4 times over 12 years. Linear mixed effects models were used to examine the association between AKAP6 and MIR2113 with cognitive performance in episodic memory, working memory, vocabulary, perceptual speed and reaction time at baseline and with linear and quadratic rates of change. AKAP6-rs17522122*T was associated with worse baseline performance in episodic memory, working memory, vocabulary and perceptual speed, but it was not associated with cognitive change in any domain. MIR2113-rs10457441*T was associated with accelerated decline in episodic memory. No other associations with baseline cognitive performance or with linear or quadratic rate or cognitive changes were observed for this SNP. These results confirm the previous finding that AKAP6 is associated with performance across multiple cognitive domains at baseline but not with cognitive decline, while MIR2113 primarily affects the rate at which memory declines over time.
Age-associated decline is a general process that affects all cognitive domains, although it is more pronounced in domains associated with fluid cognition (i.e. those that involve novel problem solving and speeded information processing) than domains associated with crystallized cognition [i.e. those that require stored knowledge such as vocabulary and general knowledge (Horn & Cattell 1966; Salthouse 2009)] .
There is, however, great heterogeneity in the rate of decline between individuals, with some individuals remaining relatively unimpaired across their life course, while others experience a much faster rate of deterioration which can lead to cognitive impairment or dementia (Amieva et al. 2005; Zahodne et al. 2013) . Even in the absence of dementia, age-associated cognitive decline may result in increased difficulty performing tasks involving memory and rapid information processing. Decline in cognitive performance is associated with poor decision-making (Boyle et al. 2012) , difficulty with instrumental activities of daily living (Tucker-Drob 2011; Yam & Marsiske 2013) and poor health literacy (Kobayashi et al. 2016) . Even when no single aspect of daily living is critically impaired, the cumulative effect of small effects in multiple domains can have a major impact on quality of life. Furthermore, a faster rate of decline is associated with dementia (Amieva et al. 2005; Zahodne et al. 2013) and mortality (Batterham et al. 2009; Shipley et al. 2007) . Identifying factors that predispose individuals to faster cognitive decline is an important step in developing intervention and treatment strategies for maintaining cognitive health.
Genetic factors contribute to the inter-individual variability observed in cognitive decline, with common genetic variants estimated to account for between 40% and 50% of the variability associated with general cognitive functioning in later life, and 24% of the variability in lifetime cognitive change (Davies et al. 2011; Deary et al. 2012) . A recent meta-analysis of genome-wide association studies (GWAS) performed by the CHARGE consortium (n = 53 949) identified 13 single nucleotide polymorphisms (SNPs) in three genomic regions, MIR2113 (n = 11), AKAP6 (n = 1) and APOE/TOMM40 (n = 1) associated with general cognitive function (Davies et al. 2015) . In a follow-up study of the UK Biobank (n = 112,151), MIR2113 was associated with educational attainment and verbal-numerical reasoning, AKAP6 was associated with verbal-numerical reasoning, reaction time and memory, while conversely APOE/TOMM40 was not associated with any measure of cognitive function (Davies et al. 2016) .
The APOE/TOMM40 region has been consistently associated with Alzheimer's disease (Farrer et al. 1997; Roses et al. 2010) , and in particular for APOE, with cognitive performance in episodic memory, executive functioning, perceptual speed and global cognitive ability (Wisdom et al. 2011) . In contrast, the role of AKAP6 and MIR2113 in cognitive function is not well understood. The genome-wide significant SNPs identified by Davies et al. 2015 in the MIR2113 region are located ∼100 kb downstream of MIR2113 and are associated with regulatory elements such open chromatin, histone modifications, DNase hypersensitive sites and position weight matrix sites, suggesting that the associated SNPs are in sites of active transcription and may play a regulatory role in transcription (Davies et al. 2015) . AKAP6 is highly expressed in various brain regions and cardiac and skeletal muscle where it binds to the regulatory subunit of protein kinase A (PKA) and anchors PKA to the nuclear membrane or sarcoplasmic reticulum. The cAMP-dependent PKA signalling pathway, in turn has been shown to be involved in short-and long-term memory and working memory (Bernabeu et al. 1997; Taylor et al. 1999) .
Here, we extend this previous research by investigating the association of MIR2113 and AKAP6 with baseline and longitudinal non-linear change in cognitive performance in a community-based cohort of 1570 older adults without dementia who have undergone cognitive testing in the domains of episodic memory, working memory, verbal ability, processing speed and reaction time.
Methods

Participants
Participants were from the Personality and Total Health (PATH) Through Life Project, a large community survey of heath and well-being in adults. Participants were randomly recruited from the electoral rolls of Canberra and the neighbouring town of Queanbeyan into one of three cohorts based on age; the 20+ (20-24 years), the 40+ (40-44 years) and the 60+ (60-64 years), with individuals assessed at 4-year intervals over a period of 12 years. The background and procedures of the PATH cohort have been described in detail elsewhere (Anstey et al. 2012) . Written informed consent was obtained from all participants and approval for the study was obtained from the Human Research Ethics Committee of the Australian National University.
Data collected from the 60+ cohort were used in this study, with interviews conducted in 2001-2002 (n = 2551), 2005-2006 (n = 2222), 2009-2010 (n = 1973) and 2014-2015 (n = 1645) . Individuals were excluded from analysis based on the following criteria: attendance at only one wave (n = 309); no genomic DNA available or missing genotype data (n = 264); APOE 2/ 4 carriers (n = 60, to avoid conflation of the 2 protective and 4 risk affect); non-European ancestry (n = 107); probable dementia at any wave (MMSE < 24; n = 82); self-reported medical history of epilepsy, brain tumours or infections, stroke and transient ischemic attacks (n = 381). Missing values in 'Education' (total number of years of education, n = 129) were imputed using the 'missForest' package in R (Stekhoven & Bühlmann 2012) . These exclusions left a final data set of 1570 individuals at baseline.
Cognitive assessment
All participants were assessed at baseline and at each subsequent interview for the following four cognitive abilities: perceptual speed assessed with the Symbol Digit Modalities Test (SDMT), which asks the participant to substitute as many digits for symbols as possible in 90s (Smith 2002) ; episodic memory, assessed with the Immediate Recall of the first trial of the California Verbal Learning Test, which involves recalling a list of 16 nouns (Delis et al. 1987) ; working memory, assessed with the Digit Span Backward from the Wechsler Memory Scale, which presents participants with series of digits increasing in length at the rate of one digit per second and asks them to repeat the Digits Backwards (Wechsler 1945) ; and vocabulary, assessed with the Spot-the-Word Test, which asks participants to choose the real words from 60 pairs of words and nonsense words (Baddeley et al. 1993) . Simple and choice reaction time (SRT and CRT) tasks were administrated using a hand held box with two depressible buttons, two red stimulus lights and one green 'get ready' light. SRT was measured using four blocks of 20 trials, in which the participant was instructed to press the right hand button (regardless of dominance) in response to the activation of one of the stimulus lights. Choice reaction time was measured using two blocks of 20 trials, in which participants were instructed to press the button corresponding to the left or right stimulus light. Mean reaction times were calculated as described previously (Anstey et al. 2005) . Raw cognitive test scores at each wave and Pearson correlations between wave 1 test scores are presented in Tables S1 and S2 (Supporting Information).
Genotyping
The most strongly associated SNPs identified by the CHARGE consortium, MIR211-rs10457441, AKAP6-rs17522122 and TOMM40-rs10119, were genotyped using TaqMan OpenArray Assays as previously described (Andrews et al. 2016) . For AKAP6 and MIR2113 an additive model was used which examines the effect of each minor allele.
TOMM40-rs10119 did not pass quality control in our data set and as such was excluded from the analysis. TOMM40-rs10119 is located in the 19q13.32 region, which is a gene-dense region of strong linkage disequilibrium and includes APOE and TOMM40. Fine mapping of the region indicates that APOE variation is driving observed associations with cognitive ageing (Davies et al. 2014 ). As such, we included the APOE 2/ 3/ 4 haplotypes in our analysis as covariates. SNP data for rs429358 and rs7412 which define the APOE 2/ 3/ 4 haplotypes were genotyped separately using TaqMan assays as previously described (Jorm et al. 2007) . APOE alleles were coded as the number of APOE * 4 alleles (0,1,2). Participants with the APOE * 2/ 4 allele were excluded to avoid conflation between the APOE * 2 protective and APOE * 4 risk affect.
All SNPs were in Hardy-Weinberg equilibrium (P < 0.05). Genotype frequencies are presented in Table 1 .
Statistical analysis
Statistical analysis was performed in the R 3.2.3 Computing environment (Ihaka & Gentleman 1996) . To facilitate comparisons across cognitive tests, all cognitive test results at all four waves were transformed into z-scores using the means and standard deviations at baseline. Higher scores indicate better cognitive performance.
Demographic characteristics of participants excluded or included from analysis are described using means and standard deviations for continuous variables and frequency and proportions for categorical variables (Table 1) . Demographic variables were compared using independent sample t-tests and 2 tests.
Linear mixed effects models (LMMs) adjusting for gender and APOE genotype, with maximum likelihood estimation, subjectspecific random slopes and intercepts were used to compare cognitive performance between genotypes. Longitudinal change in cognitive performance was modelled as a quadratic growth curve, where age was centred on baseline, linear rate of change (Time) was the slope at intercept, and quadratic rate of change (Time 2 ) was acceleration/deceleration of the curve over time. Quadratic growth curves were represented as orthogonal polynomials to avoid co-linearity problems and facilitate estimation of the models (Donald & Robert 2006) . Linear mixed effects models were estimated using the R package 'lme4' (Bates et al. 2015) .
Statistical significance of the fixed effects were determined using a Kenward-Roger approximation for F -tests, where a full model, containing all fixed effects, is compared with a reduced model that excludes an individual fixed effect . As this is a follow-up study to replicate the previous findings in the CHARGE consortium and UK biobank studies, a P-value <0.05 was considered statistically significant. To evaluate whether the random slopes were significantly different from 0, and to determine if there was residual variability in the rate of change that could be explained by predictor variables, LMMs that included random slopes were compared with models that did not include random slopes using parametric bootstrap methods where 1000 simulations of the likelihood ratio test statistic were generated. Conditional R 2 (R 2 c ), the variance explained by fixed and random effects (i.e. the entire model), and marginal R 2 (R 2 c ), the variance explained by the fixed effects were calculated using the R package 'MuMIn' (Barton 2013; Johnson 2014; Nakagawa & Schielzeth 2013) . Power curves were calculated to assess the effect size that could be detected at a given power for our sample size using the R package 'simr' (Green & MacLeod 2016) . The power calculations were based on Monte Carlo simulations (n = 1000) of LMMs for each of the cognitive outcomes considered, where the effect size for AKAP6 and MIR2113 baseline, linear and quadratic coefficients were altered in the base model in increments of 0.5 for the linear and quadratic coefficients and 0.02 for baseline coefficients. The power curves are shown in Fig. S1 , and the detectable effect sizes at 80% power are shown in Tables S3 and S4 .
Results
Population characteristics of the PATH cohort
Demographic information on PATH participants is presented in Table 1 . Individuals retained in the final sample had on average higher MMSE scores and more years of education than those excluded. Unconditional growth LMMs showed that all cognitive tests were associated with linear rate of change and, with the exception for Digits Backwards test, quadratic rate of change (Table S5) . Random slopes for all cognitive tests scores were significantly different from 0, indicating that there was sufficient variability in the rate of change between participants, thus, allowing potential genetic predictors of this change to be tested (linear Table S6 shows the results of the covariates only model.
Main effects of AKAP6 and MIR2113
Parameter estimates for the associations of AKAP6 and MIR2113 with cognitive performance are presented in Table 2 . Figure 1 illustrates the differences in cognitive trajectories between AKAP6 and MIR2113 genotypes.
AKAP6-rs17522122*T was significantly associated with a lower initial status at baseline in Immediate Recall [F(1, 1571.13 
Discussion
In this study, we investigated whether SNPs in MIR2113 and AKAP6, which were previously found to be associated with *P < 0.05; **P < 0.01; ***P < 0.00.
cognitive performance in two large GWAS studies, were also associated with cognitive decline. AKAP6 was not associated with decline in any of the cognitive abilities tested. However, we did replicate the previously observed association with baseline cognitive performance, with AKAP6-rs17522122*T observed to be associated with worse performance in episodic memory, working memory, vocabulary and perceptual speed. In Davies et al. (2015 Davies et al. ( , 2106 , AKAP6-rs17522122*T was associated with worse general fluid cognitive performance, verbal-numerical reasoning and improved performance in reaction time and memory. The observed differences in the direction of the effect for memory and lack of replication for reaction time between our study and Davies et al. 2016 could be attributed to methodological differences in the cognitive tests. The cognitive tests utilized by Davies et al. (2016) were brief bespoke, non-standard tests, with the memory test involving the recall of a single 12-item matrix that contained six pairs of matching symbols, with participants instructed to select the matching pairs after observing the matrix for 5 seconds in the fewest number of attempts; and reaction time assessed using eight trials of a computerized snap game where participants were directed to push a button if two matching symbols were observed. The memory test has been shown to have low reliability across time (Lyall et al. 2016) . Furthermore, both tests may be susceptible to floor/ceiling effects, where at the upper and lower limits, the tests may not be able to distinguish between true differences in participant abilities (Lyall et al. 2016) . In addition, differences in participant's demographics (i.e. age, education and comorbidities) and sample size may result in differential effects sizes, with participants in the UK Biobank being on average 5 years younger and less educated (30.5% vs. 76.3% with post school qualifications) than those in PATH. Another possibility is that our study was insufficiently powered, with a dramatically smaller sample size than the UK Biobank.
MIR2113 was associated with an accelerated rate of decline in episodic memory. We did not replicate the previous findings of the association between MIR2113-rs10457441*T and worse general fluid cognitive performance. It should be noted, however, that Davies et al. (2015) used principal component analysis to derive a measure of general cognitive function from cognitive tasks testing at least three different cognitive domains. When investigating individual cognitive domains, Davies et al. (2016) found that MIR2113-rs10457441*T was associated with verbal-numerical reasoning, but not with reaction time and memory. Davies et al. (2016) suggested that the association with verbal-numerical reasoning may reflect the higher loading that verbal and reasoning abilities have on general cognitive function in comparison to memory and processing speed. As such, our results and those of Davies et al. (2015 Davies et al. ( , 2016 suggest that MIR2113 may be associated with general cognition rather than specific cognitive abilities. This study has a number of strengths that allow for robust statistical modelling of the association of genetic risk factors with cognitive performance. First, this study investigated cognitive change in a randomly selected community dwelling cohort of older adults, and as such the results are likely generalizable to other populations of older adults. Second, the participants were followed for 12 years and were assessed on four occasions in five separate cognitive domains, allowing for the examination of non-linear declines across a broad spectrum of cognitive abilities. Finally, the narrow age range of the cohort reduced the potential impact of the confounding of age differences with ageing. Despite these strengths, the results from this study should be interpreted with consideration to some study limitations. First, the sample was better educated than the population from which it was drawn. As higher education is associated with a reduced rate of decline this may limit our ability to observe an association with cognitive performance. Second, only the most strongly associated SNP identified by the CHARGE consortium at each locus was genotyped. These SNPs are unlikely to be the causal variants, but are expected to be in linkage disequilibrium with other genetic variation that causes the observed associations with cognitive function. Further, 'gene'-based analyses that aggregate the effects of multiple SNPs may further elucidate the role of these loci in cognitive performance.
In conclusion, we have shown that AKAP6 does not influence the rate of cognitive decline in a population of healthy older adults. However, AKAP6 is associated with baseline cognitive performance across a broad spectrum of cognitive domains. In contrast, MIR2113 was associated with an accelerated decline in episodic memory; however, we did not observe an association with baseline cognitive performance. These results extend upon those reported by Davies et al. (2015 Davies et al. ( , 2016 , further elucidating the role these of loci in cognitive performance. Fellowship no. 1002560. The authors report no conflict of interests.
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